Skip to main content
Top
Published in: Diabetologia 9/2010

01-09-2010 | Short Communication

DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes

Authors: A. Hoverfelt, R. Sallinen, J. M. Söderlund, C. Forsblom, K. Pettersson-Fernholm, M. Parkkonen, P.-H. Groop, M. Wessman, on behalf of the FinnDiane Study Group

Published in: Diabetologia | Issue 9/2010

Login to get access

Abstract

Aims/hypothesis

The AGE receptors 1, 2 and 3, which are encoded by DDOST, PRKCSH and LGALS3, respectively, may be involved in the pathogenesis of diabetic complications. We sought to find out whether these genes are associated with diabetic nephropathy, cardiovascular disease and type 1 diabetes or related quantitative traits.

Methods

Using the Tagger program, we selected 28 single nucleotide polymorphisms (SNPs) based on the HapMap Centre d’Etude du Polymorphisme (Utah residents with northern and western European ancestry) data. The SNPs were genotyped in 2,719 Finnish patients with type 1 diabetes and tested for association with diabetic nephropathy (821 cases, 1,060 controls), cardiovascular disease and related quantitative traits. For association analysis with type 1 diabetes, 703 non-diabetic control participants were genotyped.

Results

We found evidence of genotype association between diabetic nephropathy and the SNPs rs2170336 in DDOST (p = 0.03), rs311788 in PRKCSH (p = 0.04) and rs311778 in PRKCSH (p = 0.02). However, these associations did not reach the significance limit of 0.0008 adjusted for multiple testing. None of the DDOST, PRKCSH or LGALS3 SNPs were associated with quantitative traits related to diabetic nephropathy, including AER and estimated GFR. No associations were found between the SNPs and cardiovascular disease, blood pressure, serum lipid levels or type 1 diabetes.

Conclusions/interpretation

The common SNPs tested in DDOST, PRKCSH and LGALS3 do not seem to be associated with diabetic micro- or macrovascular complications or with type 1 diabetes in Finnish patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ahmed N (2005) Advanced glycation endproducts—role in pathology of diabetic complications. Diab Res Clin Pract 67:3–21CrossRef Ahmed N (2005) Advanced glycation endproducts—role in pathology of diabetic complications. Diab Res Clin Pract 67:3–21CrossRef
2.
go back to reference Pettersson-Fernholm K, Forsblom C, Hudson BI et al (2003) The functional −374T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52:891–894CrossRefPubMed Pettersson-Fernholm K, Forsblom C, Hudson BI et al (2003) The functional −374T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52:891–894CrossRefPubMed
3.
go back to reference Prevost G, Fajardy I, Besmond C et al (2005) Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diab Metab 31:35–39CrossRef Prevost G, Fajardy I, Besmond C et al (2005) Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diab Metab 31:35–39CrossRef
4.
go back to reference Lindholm E, Bakhtadze E, Sjogren M et al (2006) The −374T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia 49:2745–2755CrossRefPubMed Lindholm E, Bakhtadze E, Sjogren M et al (2006) The −374T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia 49:2745–2755CrossRefPubMed
5.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed
6.
go back to reference Lundmark PE, Liljedahl U, Boomsma D et al (2008) Evaluation of HapMap data in six populations of European descent. Eur J Hum Genet 16:1142–1150CrossRefPubMed Lundmark PE, Liljedahl U, Boomsma D et al (2008) Evaluation of HapMap data in six populations of European descent. Eur J Hum Genet 16:1142–1150CrossRefPubMed
7.
go back to reference Poirier O, Nicaud V, Vionnet N et al (2001) Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 50:1214–1218CrossRefPubMed Poirier O, Nicaud V, Vionnet N et al (2001) Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 50:1214–1218CrossRefPubMed
8.
go back to reference Vlassara H, Brownlee M, Cerami A (1985) High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588–5592CrossRefPubMed Vlassara H, Brownlee M, Cerami A (1985) High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588–5592CrossRefPubMed
9.
go back to reference He CJ, Koschinsky T, Buenting C, Vlassara H (2001) Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 7:159–168PubMed He CJ, Koschinsky T, Buenting C, Vlassara H (2001) Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 7:159–168PubMed
10.
go back to reference Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H (2004) Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 101:11767–11772CrossRefPubMed Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H (2004) Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 101:11767–11772CrossRefPubMed
11.
go back to reference Iacobini C, Menini S, Oddi G et al (2004) Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 18:1773–1775PubMed Iacobini C, Menini S, Oddi G et al (2004) Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 18:1773–1775PubMed
12.
go back to reference Lettre G, Rioux JD (2008) Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 17:R116–R121CrossRefPubMed Lettre G, Rioux JD (2008) Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 17:R116–R121CrossRefPubMed
13.
go back to reference Saraheimo M, Forsblom C, Thorn L et al (2008) Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diab Care 31:1165–1169CrossRef Saraheimo M, Forsblom C, Thorn L et al (2008) Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diab Care 31:1165–1169CrossRef
Metadata
Title
DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes
Authors
A. Hoverfelt
R. Sallinen
J. M. Söderlund
C. Forsblom
K. Pettersson-Fernholm
M. Parkkonen
P.-H. Groop
M. Wessman
on behalf of the FinnDiane Study Group
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1771-3

Other articles of this Issue 9/2010

Diabetologia 9/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.